Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill amends Medicare drug inflation rebate rules to (1) extend or clarify inflation rebate calculations to include drugs sold in the commercial market for both Part B and Part D, (2) change the base year used to calculate inflationary increases from 2020/2021 back to 2015/2016, and (3) exclude certain units (Medicaid, some rebates, and beginning 2026 340B discounts) from unit counts. Part D changes take effect for applicable periods beginning October 1, 2025; Part B changes apply to calendar quarters beginning January 1, 2026.
Left emphasizes consumer savings and closing loopholes
Relative to its intended legislative type, this bill is a direct and specific statutory amendment that clearly integrates into the existing Social Security Act framework and supplies concrete calculation mechanics and effective dates.
The bill amends Medicare drug inflation rebate rules to (1) extend or clarify inflation rebate calculations to include drugs sold in the commercial market for both Part B and Part D, (2) change the base year used to calculate inflationary increases from 2020/2021 back to 2015/2016, and (3) exclude certain units (Medicaid, some rebates, and beginning 2026 340B discounts) from unit counts.
Part D changes take effect for applicable periods beginning October 1, 2025; Part B changes apply to calendar quarters beginning January 1, 2026.
Technically targeted but politically high-profile and opposed by well-resourced industry interests; lacks clear compromise features.
Relative to its intended legislative type, this bill is a direct and specific statutory amendment that clearly integrates into the existing Social Security Act framework and supplies concrete calculation mechanics and effective dates. It includes some protections against double-counting and defines data sources and limited Secretary responsibilities.
Left emphasizes consumer savings and closing loopholes
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes consumer savings and closing loopholes
This persona will likely view the bill favorably as a stronger tool to hold drug manufacturers accountable for price increases.
They will see expanded inflation rebates and an earlier base year as mechanisms to reduce net drug prices and protect families.
They may note exclusions to avoid double-counting are appropriate.
A pragmatic centrist will see potential public benefits in curbing inflationary price increases but will worry about implementation, cost-shifting, and unintended market responses.
They will weigh likely savings against administrative complexity, enforcement feasibility, and potential impacts on innovation or access.
This persona will likely oppose the bill as increased federal intervention that raises compliance costs and risks discouraging pharmaceutical investment.
They will view changing the base year and expanding rebates to commercial sales as retroactive-like penalties and a market distortion.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically targeted but politically high-profile and opposed by well-resourced industry interests; lacks clear compromise features.
The bill has not accumulated any surfaced votes yet.
Left emphasizes consumer savings and closing loopholes
Technically targeted but politically high-profile and opposed by well-resourced industry interests; lacks clear compromise features.
Relative to its intended legislative type, this bill is a direct and specific statutory amendment that clearly integrates into the existing Social Security Act framework and supplies concrete calculation mechanics and e…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.